A Multicentre Cohort Study of Screening and Preventive Intervention for Latent Tuberculosis Infection in Children

  • End date
    Dec 31, 2021
  • participants needed
  • sponsor
    Beijing Children's Hospital
Updated on 23 January 2021


The management of latent Mycobacterium tuberculosis infection is a new priority action for the WHO End Tuberculosis (TB) Strategy. However, national guidelines on latent tuberculosis infection testing and treatment have not yet been developed in children of China. Here, we present the results from the 3-year follow-up of a study that aimed to track the development of active disease in individuals with latent tuberculosis infection, identify priority populations for latent infection management, and explore the most suitable latent infection diagnostic approach.


  1. Baseline analysis of a population-based, multicentre, prospective cohort study
    1. A baseline survey of a population-based, multicentre, prospective cohort study were took in children (18).
    2. Eligible participants were identifi ed by door-to-door survey with a household sampling design.
    3. Participants were screened for active tuberculosis and history of tuberculosis then used a tuberculin skin test and an interferon- release assay (QuantiFERON [QFT]) to test for latent infection.
    4. Incidence of active tuberculosis in individuals with latent tuberculosis infection in children of China under different treatment regimens
    5. Individuals who had tuberculosis infection at baseline (QFT-positivity or TST tuberculin reaction size [induration] of 10 mm) were divided and treatment with different therapeutic schedule.
    6. Follow-up study were conducted to assess the proportion of latent TB infection converted to active TB

Condition Children LTBI
Treatment INH、RFT
Clinical Study IdentifierNCT04156568
SponsorBeijing Children's Hospital
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Children (0-18 years old)
Children with QFT-positive or TST induration 10 mm)

Exclusion Criteria

Patients are allergic to anti-tuberculsis drugs
Parents and/or guardians do not agree to participate in this study
Participants with active tuberculosis
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note